Fortunately, the memory of Covid-19 is fading little by little and the pandemic is losing weight on the political agenda. Specifically, the European Commission announced this Friday that it has reformulated its agreement with the pharmaceutical company Pfizer-BioNTech to reduce and slow down the rate of deliveries of Covid vaccines to the countries of the European Union. A modification of which the community executive has not given many details, reports EFE, but which is based on what has been considered “the improvement of the epidemiological situation.”
Specifically, from the Commission, they have specified that the new agreement affects the so-called “optional” doses signed by the member states of the European Union through the joint purchasing platform. In addition, they have ensured that “the modification of the existing vaccine supply contract takes into account the improvement of the epidemiological situation, while continuing to guarantee access to the latest available version of the vaccine, in the event that worrisome variables appear before covid -19 in the future”, he pointed out.
Specifically, the countries will pay “a fee” for these vaccines that can be deducted from the price they will have to pay if there is a reactivation of orders for additional doses in the future.
The community executive has avoided giving more information about the quantities and prices as it is “sensitive commercial information” contractually protected by confidentiality. In any case, the European Commissioner for Health, Stella Kyriakides, pointed out in a statement that the European Union has managed to control the pandemic “largely through our vaccines and vaccination. And although covid-19 is no longer an emergency global health, remains a threat that is likely here to stay. Therefore, it is crucial that we are prepared for the years ahead.”
A contract of at least 900 million
The European Commission, on behalf of the Twenty-seven, completed a contract with the German-American pharmaceutical consortium for a consignment of 900 million doses, with an option for another 900 million. Of the initial order, 450 doses can be delivered in 2021 and 2022 and another 450 million in 2023.